Leo Pharma elaborates on 2030 strategy after new capital injection
Backed by Nordic Capital, Leo Pharma is now free to power ahead with the strategy that will ideally lead to Leo Pharma becoming a global, leading player in medical dermatology by 2030, according to CEO Catherine Mazzacco.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Read this article for free
Register with your E-mail. No credit card required.
The number of endoscopes sold is significantly higher than what the market had predicted in Ambu's second quarter. However, this has not brought about the kind of revenue that analysts had expected. The full-year outlook is maintained.
Ambu is intensifying its efforts to create the next generation of its duodenoscopes. A number of competitors are circling, and an upcoming tender is a good opportunity for income. CEO Juan Jose Gonzalez calls the new duodenoscope the biggest earner of the future.
US electronics company Bose's announced launch of a new, cheap self-tuning hearing aid won't cause sales to plummet for established hearing aid manufacturers, analysts believe. Demant welcomes the competition and WSA plans to test Bose's new solution to understanding its technology.